Bloom Burton Comments on Cybin Inc.’s FY2025 Earnings (NYSE:CYBN)

Cybin Inc. (NYSE:CYBN) – Equities researchers at Bloom Burton cut their FY2025 earnings per share estimates for shares of Cybin in a report issued on Monday, August 12th. Bloom Burton analyst D. Martin now expects that the company will earn ($0.09) per share for the year, down from their prior estimate of ($0.08). The consensus estimate for Cybin’s current full-year earnings is ($0.09) per share. Bloom Burton also issued estimates for Cybin’s FY2026 earnings at ($0.10) EPS.

A number of other research firms have also commented on CYBN. Cantor Fitzgerald restated an “overweight” rating on shares of Cybin in a research report on Wednesday, July 31st. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Cybin in a research note on Wednesday, July 31st.

Cybin Price Performance

Cybin stock opened at $0.26 on Wednesday. Cybin has a 1-year low of $0.24 and a 1-year high of $0.74. The company has a market cap of $108.05 million, a price-to-earnings ratio of -1.32 and a beta of 0.43. The business’s 50 day moving average price is $0.28.

Cybin (NYSE:CYBN) last announced its quarterly earnings results on Wednesday, June 26th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. PEAK6 Investments LLC bought a new stake in Cybin during the first quarter valued at approximately $95,000. AdvisorShares Investments LLC raised its position in shares of Cybin by 13.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock valued at $494,000 after buying an additional 220,403 shares in the last quarter. AWM Investment Company Inc. bought a new stake in shares of Cybin during the 1st quarter worth $930,000. Rosalind Advisors Inc. grew its position in Cybin by 38.3% in the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock worth $5,230,000 after acquiring an additional 5,340,000 shares in the last quarter. Finally, Ikarian Capital LLC bought a new position in Cybin in the first quarter valued at $5,770,000. Hedge funds and other institutional investors own 17.94% of the company’s stock.

Cybin Company Profile

Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.